New diabetes shot UBT38006 enters first human safety trial
NCT ID NCT07630233
First seen Jun 27, 2026 · Last updated Jul 21, 2026 · Updated 2 times
Summary
This early-stage trial tests a single injection of UBT38006 in 43 healthy adult men to see if it is safe and how the body processes it. Participants receive either the drug, a placebo, or an active comparator (insulin degludec). The goal is to gather safety data and measure drug levels in the blood, not yet to treat diabetes.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- UBT38006 injection
- What this could lead to
- If successful, this could point toward a new, longer-acting diabetes treatment that requires fewer injections.
- What could go wrong
- This is a very early Phase 1 trial in only 43 healthy men, not people with diabetes. It primarily checks safety, not effectiveness, and many early-stage drugs fail to advance.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES MELLITUS (T2DM) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The Second Hospital of Anhui Medical University
Hefei, Anhui, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could your gut bacteria hold the key to protecting your kidneys?
- Muscle-Saving supplement may shield seniors from Weight-Loss drug side effect
- Can diabetes disrupt the Brain-Heart link?
- A scent of citrus: could bitter orange oil ease fatigue and aid sleep in diabetes?
- Gut bacteria swap may tame diabetes and thyroid disease
- A blood marker may reveal how well diabetes treatments are working